These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 782698)

  • 41. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
    Creagan ET; Eagan RT; Rubin J
    Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 43. Pulmonary veno-occlusive disease following therapy for malignant neoplasms.
    Lombard CM; Churg A; Winokur S
    Chest; 1987 Nov; 92(5):871-6. PubMed ID: 3665603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carmustine (BiCNU).
    Med Lett Drugs Ther; 1978 Sep; 20(18):79-80. PubMed ID: 692493
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of Hodgkin's disease.
    Carter SK; Goldsmith MA
    Lancet; 1973 Feb; 1(7797):264. PubMed ID: 4119407
    [No Abstract]   [Full Text] [Related]  

  • 46. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).
    Durant JR; Norgard MJ; Murad TM; Bartolucci AA; Langford KH
    Ann Intern Med; 1979 Feb; 90(2):191-4. PubMed ID: 443651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCNU (carmustine).
    Burnham N; Betcher DL
    J Assoc Pediatr Oncol Nurses; 1989; 6(1):23-5. PubMed ID: 2921741
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
    Nissen NI; Larsen V; Pedersen H; Thomsen K
    Cancer Chemother Rep; 1972 Dec; 56(6):769-77. PubMed ID: 4634038
    [No Abstract]   [Full Text] [Related]  

  • 49. Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU).
    Weiss RB; Muggia FM
    Ann Intern Med; 1979 Jul; 91(1):131-2. PubMed ID: 464441
    [No Abstract]   [Full Text] [Related]  

  • 50. Do information systems improve the quality of clinical research? Results of a randomized trial in a cooperative multi-institutional cancer group.
    Wirtschafter DD; Scalise M; Henke C; Gams RA
    Comput Biomed Res; 1981 Feb; 14(1):78-90. PubMed ID: 7237997
    [No Abstract]   [Full Text] [Related]  

  • 51. Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU).
    Kaplan RL
    Ann Intern Med; 1979 Jul; 91(1):131. PubMed ID: 464440
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.
    Dolan ME; Larkin GL; English HF; Pegg AE
    Cancer Chemother Pharmacol; 1989; 25(2):103-8. PubMed ID: 2557168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery systems.
    Raghavan K; Loftsson T; Brewster ME; Bodor N
    Pharm Res; 1992 Jun; 9(6):743-9. PubMed ID: 1409355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
    Williams SF; Bitran JD
    Hematol Oncol Clin North Am; 1989 Jun; 3(2):319-30. PubMed ID: 2663830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
    Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.
    Gams RA; Durant JR; Bartolucci AA
    Cancer Treat Rep; 1982 Apr; 66(4):899-905. PubMed ID: 7042089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
    Anderson T; DeVita T; Young RC
    Cancer Treat Rep; 1976 Jun; 60(6):761-7. PubMed ID: 782698
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.